World's Best Scientists 2026 revealed!
Richard M. Scearce

Richard M. Scearce

D-Index & Metrics

Immunology

D-Index
50
Citations
9601
World Ranking
4237
National Ranking
1930

Richard M. Scearce publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Richard M. Scearce sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 100 publications — 3rd percentile

3% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Richard M. Scearce D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Richard M. Scearce sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 50 D-Index — 15th percentile

15% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Richard M. Scearce is affiliated with Duke University in the United States. Their work primarily focuses on immunology and microbiology, with additional research contributions in biochemistry, genetics, and molecular biology. The scientist's expertise spans several subfields including immunology, virology, molecular biology, radiology, nuclear medicine and imaging, and infectious diseases.

The main research topics covered by Richard M. Scearce include:

  • HIV Research and Treatment
  • Immunotherapy and Immune Responses
  • Immune Cell Function and Interaction
  • T-cell and B-cell Immunology
  • Monoclonal and Polyclonal Antibodies Research
  • Glycosylation and Glycoproteins Research
  • RNA Interference and Gene Delivery

Several notable recent papers authored or coauthored by Scearce include:

  • Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates, 2021, npj Vaccines
  • Immune checkpoint modulation enhances HIV-1 antibody induction, 2020, Nature Communications
  • Stabilized HIV-1 envelope immunization induces neutralizing antibodies to the CD4bs and protects macaques against mucosal infection, 2022, Science Translational Medicine
  • Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates, 2020, bioRxiv (Cold Spring Harbor Laboratory)
  • Mouse and human antibodies bind HLA-E-leader peptide complexes and enhance NK cell cytotoxicity, 2022, Communications Biology

The scientist frequently publishes in venues such as:

  • UNC Libraries
  • npj Vaccines
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Nature Communications
  • Science Translational Medicine

Richard M. Scearce regularly collaborates with several coauthors, including:

  • Robert Parks
  • Barton F. Haynes
  • Kevin O. Saunders
  • Maggie Barr
  • David C. Montefiori

Best Publications

  • Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

    Hua-Xin Liao;Rebecca Lynch;Tongqing Zhou;Feng Gao;Feng Gao

  • Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies

    Barton F. Haynes;Judith Fleming;E. William St. Clair;Herman Katinger

  • Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination

    Norbert Pardi;Michael J. Hogan;Rebecca S. Pelc;Hiromi Muramatsu

  • Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses.

    Norbert Pardi;Michael J. Hogan;Martin S. Naradikian;Kaela Parkhouse

  • The Role of Antibody Polyspecificity and Lipid Reactivity in Binding of Broadly Neutralizing Anti-HIV-1 Envelope Human Monoclonal Antibodies 2F5 and 4E10 to Glycoprotein 41 Membrane Proximal Envelope Epitopes

    S. Munir Alam;Mildred McAdams;David Boren;Michael Rak

  • A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses.

    Hua Xin Liao;Laura L. Sutherland;Shi Mao Xia;Mary E. Brock

  • Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group M consensus envelope glycoprotein

    Feng Gao;Eric A. Weaver;Zhongjing Lu;Yingying Li

  • Human Immunodeficiency Virus Type 1 gp41 Antibodies That Mask Membrane Proximal Region Epitopes: Antibody Binding Kinetics, Induction, and Potential for Regulation in Acute Infection

    S. Munir Alam;Richard M. Scearce;Robert J. Parks;Kelly Plonk

  • Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes.

    T J Palker;T J Matthews;A Langlois;M E Tanner

  • Phenotypic characterization and ontogeny of mesodermal-derived and endocrine epithelial components of the human thymic microenvironment.

    B F Haynes;R M Scearce;D F Lobach;L L Hensley

  • Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46.

    T J Palker;M E Tanner;R M Scearce;R D Streilein

  • Targeted selection of HIV-specific antibody mutations by engineering B cell maturation.

    Kevin O. Saunders;Kevin Wiehe;Ming Tian;Priyamvada Acharya

  • Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge

    Todd Bradley;Justin Pollara;Sampa Santra;Nathan Vandergrift

  • Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides.

    Mary Kate Hart;Kent J. Weinhold;Richard M. Scearce;Eileen M. Washburn

  • HIV-1 Envelope gp41 Antibodies Can Originate from Terminal Ileum B Cells that Share Cross-Reactivity with Commensal Bacteria

    Ashley M. Trama;M. Anthony Moody;S. Munir Alam;Frederick H. Jaeger

  • Envelope Deglycosylation Enhances Antigenicity of HIV-1 gp41 Epitopes for Both Broad Neutralizing Antibodies and Their Unmutated Ancestor Antibodies

    Ben-Jiang Ma;S Munir Alam;Eden P. Go;Xiaozhi Lu

  • Differentiation of human T lymphocytes. I. Acquisition of a novel human cell surface protein (p80) during normal intrathymic T cell maturation.

    B F Haynes;E A Harden;M J Telen;M E Hemler

  • Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys.

    M K Hart;T J Palker;T J Matthews;A J Langlois

  • Cytotoxic antibodies to cloned rat islet cells in serum of patients with diabetes mellitus.

    G S Eisenbarth;M A Morris;R M Scearce

  • Removal of fibroblasts from human epithelial cell cultures with use of a complement fixing monoclonal antibody reactive with human fibroblasts and monocytes/macrophages.

    Kay H. Singer;Richard M. Scearce;Debbi T. Tuck;Leona P. Whichard

Frequent Co-Authors

Barton F. Haynes
Barton F. Haynes Duke University
Hua-Xin Liao
Hua-Xin Liao Duke University
S. Munir Alam
S. Munir Alam Duke University
David C. Montefiori
David C. Montefiori Duke University
Robert Parks
Robert Parks Duke University
M. Anthony Moody
M. Anthony Moody Duke University
Sampa Santra
Sampa Santra Beth Israel Deaconess Medical Center
Georgia D. Tomaras
Georgia D. Tomaras Duke University
Bette T. Korber
Bette T. Korber Los Alamos National Laboratory
Kevin O. Saunders
Kevin O. Saunders Duke University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in expanding their qualifications or shifting their focus within the healthcare field, several online degree options complement a background in Immunology. Transitioning from a Family Nurse Practitioner (FNP) to a more specialized role can be achieved through fnp to acute care certification, which prepares nurses for acute care settings and advanced patient management.

Online accelerated programs offer an efficient way to gain advanced nursing credentials. Aspiring nurse practitioners may explore accelerated np programs online that provide comprehensive instruction while accommodating working professionals.

For individuals without a nursing background, 12-month accelerated nursing programs online for non nurses offer a fast track to enter the nursing profession, bridging science knowledge with clinical skills. Similarly, 12-month accelerated nursing programs provide accelerated pathways to earning a Bachelor of Science in Nursing, making them accessible for career changers and recent graduates alike.

These educational pathways expand career opportunities, allowing professionals in Immunology and related fields to diversify their skill set and advance in the dynamic healthcare industry.

Best Scientists Citing Richard M. Scearce

Trending Scientists

Recently Published Articles